Capstone Investment Advisors’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-667
Closed -$164K 1713
2022
Q3
$164K Buy
+667
New +$180K ﹤0.01% 1507
2021
Q4
Sell
-1,308
Closed -$442K 2151
2021
Q3
$426K Buy
+1,308
New +$443K ﹤0.01% 1599
2020
Q1
Sell
-4,412
Closed -$732K 1415
2019
Q4
$753K Sell
4,412
-6,108
-58% -$1.13M ﹤0.01% 1066
2019
Q3
$1.87M Buy
10,520
+4,622
+78% +$999K 0.01% 749
2019
Q2
$1.54M Buy
5,898
+2,001
+51% +$531K 0.01% 815
2019
Q1
$1.11M Buy
3,897
+3,031
+350% +$1.01M 0.01% 776
2018
Q4
$281K Buy
866
+595
+220% +$207K ﹤0.01% 950
2018
Q3
$122K Buy
+271
New +$107K ﹤0.01% 1108
2017
Q3
Sell
-31,921
Closed -$4.57M 786
2017
Q2
$4.57M Buy
+31,921
New +$4.29M 0.12% 139

Other funds holding ABMD

Capstone Investment Advisors's ABMD Position: Q4 2022 in Review

Capstone Investment Advisors sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 667 shares — an estimated $164K sold.

Capstone Investment Advisors first reported a position in ABMD in Q2 2017 and held it in 9 quarters. The position peaked at $4.57M in Q2 2017. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Capstone Investment Advisors reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Capstone Investment Advisors sold 667 Abiomed Inc shares in Q4 2022, an estimated $164K.
  • Capstone Investment Advisors first reported a position in Abiomed Inc in Q2 2017 and held it in 9 quarters.
  • Capstone Investment Advisors's Abiomed Inc position peaked at $4.57M in Q2 2017.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Capstone Investment Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.